Design: Meta-analysis. Data sources and study eligibility criteria:
INTRODUCTION
Knee arthroscopic surgery is a very common surgical procedure that usually does not require hospitalisation before or after surgery. In spite of its popularity, this type of surgery can sometimes cause severe pain. 1 Solheim et al 2 reported that around 60% of patients may experience moderate to severe pain after knee arthroscopic surgery, which can delay rehabilitation and increase the risk of postoperative complications. Therefore, adequate postoperative pain control is essential and can improve postoperative convalescence.
The use of intra-articular (IA) anaesthesia after arthroscopic knee surgery became popular after a seminal publication by Stein et al 3 in 1991. Currently, bupivacaine as a local anaesthetic and morphine to relieve pain are widely used in combination to provide effective postoperative analgesia. [4] [5] [6] [7] [8] [9] [10] However, the efficacy and safety of this combination for patients undergoing knee arthroscopic surgery remains controversial. Some studies found that IA bupivacaine plus morphine provided effective pain relief for patients, [11] [12] [13] [14] [15] [16] [17] [18] [19] while others did not. [20] [21] [22] Consequently, this quantitative meta-analysis involving 12 randomised placebo-controlled trials (RCTs) was designed to examine the efficacy and safety of IA bupivacaine in combination with morphine for patients undergoing knee arthroscopic surgery.
Strengths and limitations of this study
▪ This is the first quantitative analysis to compare single-dose intra-articular (IA) bupivacaine plus morphine with saline placebo after knee arthroscopic surgery. ▪ All included studies in this meta-analysis adopted a randomised placebo-controlled design. ▪ A comprehensive report on the effects of singledose IA bupivacaine plus morphine after knee arthroscopic surgery is provided. ▪ Substantial heterogeneity was observed in the number of patients requiring supplementary analgesia and the time to first analgesic request. ▪ None of the observation periods of the included studies were long enough to detect cartilage toxicity.
MATERIALS AND METHODS Search strategy
This meta-analysis was performed in accordance with the PRISMA guidelines. 23 PubMed/Medline (1966-2014), the Cochrane Central Register of Controlled Trials (CENTRAL) and Embase databases were searched for relevant studies comparing bupivacaine plus morphine with placebo in patients receiving a single-dose IA injection after knee arthroscopic surgery. Search terms were 'arthroscopy', 'arthroscopic', 'arthroscope', 'morphine', 'bupivacaine' and 'randomised controlled trials'. No restrictions were imposed. The references and reviews of the retrieved studies were also assessed.
Study selection
The citations and abstracts generated by the literature search were reviewed by two researchers independently.
Inclusion criteria were as follows: (a) patients undergoing knee arthroscopic surgery; (b) administration of combination therapy of single-dose IA bupivacaine and morphine for postoperative pain relief; (c) RCTs; and (d) administration of saline in the control group. Exclusion criteria were as follows: (a) non-RCTs; (b) non-placebo-controlled trials; (c) the combination therapy of single-dose IA bupivacaine and morphine not administered in the experimental group; (d) data not available for extraction; and (e) unavailability of the full text.
Data extraction
The two independent researchers used Review Manager V.5.2 software (RevMan V.5.2; The Cochrane Collaboration, Oxford, UK) to record and manage information. The SD of outcome, if not reported, was estimated based on sample size, the SE or the 95% CI. Data were also extracted from figures by using GetData V.2.20 3 Open Access software. If there were more than two experimental groups in one study, data were extracted only for the bupivacaine plus morphine group and the placebo group. The basic information extracted from the studies included: first author, year of publication, mean age, sex ratio, number of patients in the experimental and control groups, doses of bupivacaine and morphine, concentration of bupivacaine, follow-up time points, type of anaesthesia, epinephrine used, type of surgery, IA injection time, and modified Oxford scores (MOS). 24 25 MOS was assessed by the two independent researchers and used to measure the quality of each study according to the method of randomisation, concealment allocation, blinding and follow-up. Any disagreements between the two researchers were resolved by discussion. The primary outcomes of interest were pain intensity, which was assessed on a visual analogue scale (VAS), and side effects. The secondary outcomes were the number of patients requiring supplementary analgesia and the time to first request for analgesia. 
Statistical analyses
Quantitative analysis was performed for pain intensity reported using a VAS, and the time to first request for analgesia. We calculated weighted mean differences (WMDs) and their corresponding 95% CIs. Dichotomous data on side effects and number of patients requiring supplementary analgesia were summarised using risk ratios (RRs) and their corresponding 95% CIs. Bupivacaine and morphine were used in different doses, and pain intensity was reported at different follow-up time points in the various studies. In order to facilitate and standardise pooling of data, each group was regarded as a single study, and we computed the mean and SD of mean VAS scores across the different time points of each study. We also analysed the VAS scores at the last follow-up time point (last VAS scores). All VAS scores were converted to a scale ranging from 0 to 10. The homogeneity of effect size across trials was tested with the Q statistic ( p≤0.05 was considered heterogeneous). If there was significant heterogeneity among studies, the random-effects model was used; otherwise, the fixed-effects model was employed. We also examined the I 2 statistic, which measures the percentage of the total variation across studies which results from heterogeneity rather than chance (I 2 ≥50% was considered moderately or very heterogeneous). A sensitivity analysis was conducted to examine the influence of various exclusion criteria on overall effect sizes.
Begg's tests 26 and funnel plots were used to assess publication bias. We used RevMan V.5.2 and STATA V.12.0 (StataCorp LP, College Station, Texas, USA) to perform statistical analyses. p<0.05 was considered to be statistically significant, unless otherwise stated.
RESULTS
The search strategy identified 511 articles, the full texts of 36 of which were assessed. Eventually, 12 articles [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] were included in the meta-analysis (figure 1). The characteristics of these 12 studies are given in table 1, and the MOS of each study are listed in table 2. 
VAS values
All 12 included articles [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] reported pain intensity using VAS scores, but one 21 only reported the mean VAS score values. Therefore, 11 studies 11-20 22 involving 320 patients were eligible for assessment of postoperative pain intensity. The bupivacaine plus morphine group demonstrated significantly lower mean VAS scores (WMD −1.58; 95% CI −2.16 to −1.01; p<0.001) and last VAS scores (WMD −1.53; 95% CI −1.98 to −1.09; p<0.001) compared to the placebo group. Substantial heterogeneity was observed in both mean VAS scores (I 2 =56%; p=0.01) and last VAS scores (I 2 =63%; p=0.003). The results are shown in figure 2A , B.
Sensitivity analysis explored the potential sources of heterogeneity between the bupivacaine plus morphine group and the placebo group and investigated the influence of various exclusion criteria on the overall risk estimate. The results are presented in table 3. The overall WMD of mean VAS scores did not vary substantially with the exclusion of any single study, and ranged from −1.15 (95% CI −1.47 to −0.83) to −1.75 (95% CI −2.16 to −1.33). The overall WMD of last VAS scores did not vary substantially with the exclusion of any single study either, and ranged from −1.46 (95% CI −1.63 to −1.29; p<0.001) to −1.70 (95% CI −1.89 to −1.50; p<0.001). In addition, the substantial heterogeneity in mean VAS scores was materially changed by excluding Brandsson figure 4 .
Sensitivity analysis showed inconsistency in the results (table 3) . There was no significant difference in the results (RR 0.66; 95% CI 0.43 to 1.02; p=0.06) after excluding one study 15 where treatment also included epinephrine. Further exclusion of single studies indicated that the overall RR only changed substantially when the study by Hosseini et al 11 was excluded (RR 0.64; 95% CI 0.39 to 1.05; p=0.08). Begg's funnel plot did not show any substantial asymmetry, and Begg's rank correlation test did not indicate publication bias among the included studies ( p=0.902).
Time to first analgesic request Three articles 11 16 21 reported the time interval until the first request for additional analgesia. The combined data suggested no significant difference (WMD 3.46; 95% CI −1.81 to 8.72; p=0.20) between the bupivacaine plus morphine group and the placebo group. Great heterogeneity (I 2 =100%; p<0.001) was observed. The results are presented in figure 5. Begg's funnel plot did not show any substantial asymmetry, and Begg's rank correlation test did not indicate publication bias among the included studies ( p=1.000).
Side effects
Three articles 11 12 21 evaluated side effects including nausea, vomiting, headache, pruritus and respiratory depression. Pooled data analysis revealed that there was no significant difference in side effects between the bupivacaine plus morphine group and the placebo group (RR 1.67; 95% CI 0.65 to 4.26; p=0.29). No substantial heterogeneity was observed (I 2 =0%; p=0.91). The results are presented in figure 6. Begg's funnel plot did not show any substantial asymmetry, and Begg's rank correlation test did not indicate publication bias among the included studies ( p=1.000).
DISCUSSION
This quantitative meta-analysis involving 12 RCTs [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] showed that the combination therapy of single-dose IA bupivacaine and morphine is effective for pain relief after knee arthroscopic surgery. There was no significant difference between the two groups in terms of side effects.
Separate IA administration of bupivacaine or morphine alone has been reported to provide good postoperative analgesia after arthroscopic knee surgery. [27] [28] [29] Eroglu et al 30 further demonstrated the efficacy and safety of low-dose IA bupivacaine and morphine for spinal anaesthesia in outpatients after knee arthroscopic surgery. However, the efficacy and safety of combination therapy with IA bupivacaine and morphine remain controversial. This meta-analysis suggests that the administration of single-dose IA bupivacaine plus morphine is Figure 6 Forest plot of side effects.
effective for pain relief after knee arthroscopic surgery, while its short-term side effects are similar to those of saline placebo.
The results described above are supported by some studies [11] [12] [13] [14] [15] [16] [17] [18] [19] but not by others. [20] [21] [22] The conflicting findings may be due to various factors. Ruwe et al 31 suggested that patients with preoperative pain were more likely to experience postoperative pain, so they regarded preoperative pain as a significant variable. Epinephrine may be another confounding factor. Haynes et al 32 reported that the addition of epinephrine could decrease the effectiveness of morphine in the combination group. However, Allen's study 27 indicated that the addition of epinephrine did not weaken the analgesic effect of IA bupivacaine plus morphine, but could rather prolong the duration of analgesia. Furthermore, Reuben and Sklar 33 suggested that inflammation at the site of surgical trauma would cause increased postoperative pain, but this was not considered in our study.
The findings of this meta-analysis suggest that there was no significant difference (WMD 3.46; 95% CI −1.81 to 8.72; p=0.20) between the bupivacaine plus morphine group and the placebo group in terms of time to first analgesic request. However, McSwiney et al 34 reached an opposite conclusion. They considered that the combination therapy of single-dose IA bupivacaine plus morphine should provide longer duration of analgesia. However, the small number of studies included in their report may have influenced this finding.
In this meta-analysis, three studies 11 12 21 reported the rate of side effects in both the bupivacaine plus morphine group and the placebo group. Most of the included studies 13 14-20 22 suggested that side effects were infrequent, and there was no statistically significant difference between the two groups. However, it is worth noting that in none of the included studies was the observation period long enough to detect the important side effect of cartilage toxicity following IA bupivacaine or morphine. Some reports [35] [36] [37] [38] [39] indicated that IA bupivacaine might cause cartilage toxicity, while other claimed that IA bupivacaine is safe. [40] [41] [42] However, IA morphine appeared to be an effective and less toxic analgesic. 43 44 Therefore, we can only conclude that single-dose IA bupivacaine plus morphine after knee arthroscopic surgery is safe in the short term.
This meta-analysis has several strengths. First, all included studies adopted a randomised placebocontrolled design, which improves comparability between groups and reduces the risk of selection bias. Second, it provides a comprehensive report of the effects of single-dose IA bupivacaine plus morphine after knee arthroscopic surgery. Based on pooled evidence from 12 RCTs conducted in a wide range of geographical locations, with different patient characteristics, baseline illness status and ethnicity, the findings of this meta-analysis have sufficient external validity to be generalised to a broader population. Last, this is the first quantitative analysis to compare single-dose IA bupivacaine plus morphine with saline placebo after knee arthroscopic surgery. The findings are therefore more reliable than those of previous reviews and RCTs.
The limitations of this meta-analysis should also be acknowledged. First, some potentially relevant RCTs were excluded for reasons such as publication in a language other than English, non-availability of extractable data, and non-availability of the full text. Therefore, the statistical power of the tests was limited due to the relatively small number of studies available for analysis of each variable. Second, substantial heterogeneity was observed in the number of patients requiring supplementary analgesia and the time to first analgesic request. Various potential confounding factors, such as variable dosage of administered medications and different follow-up times, may have contributed to this heterogeneity. In particular, although there was no significant difference in the time to first analgesic request between the two groups, the result was not absolutely reliable because of the great heterogeneity among the three studies 11 16 21 (I 2 =100%; p<0.001). Finally, observation periods were not long enough to determine if cartilage toxicity, an important side effect, was caused by IA bupivacaine or morphine.
CONCLUSIONS
In conclusion, this meta-analysis of RCTs suggests that the administration of single-dose IA bupivacaine plus morphine after knee arthroscopic surgery is effective for pain relief, and that its short-term side effects are similar to those of saline placebo.
